Implicity

What does the platform cover?

The vendor calls itself "a pioneer in SaaS agnostic platforms for CIED remote monitoring." Its named products are SignalHF, the ILR ECG Analyzer, InLink, AF Alert Management, Patient Connectivity Management and a Dynamic Billing Engine. The homepage shows logos of Abbott, Biotronik, Boston Scientific, Medtronic and MicroPort.

According to the vendor, SignalHF scores heart failure risk from implant data and alerts when a threshold is crossed. The ILR ECG Analyzer reclassifies events from insertable cardiac monitors, and AF Alert Management filters atrial fibrillation burden notifications.

What has the FDA cleared?

Implicity, Inc. holds three 510(k) clearances. K210543 was decided on November 3, 2021 for IM007. K230842 was decided on October 25, 2023 for SignalHF (IM008). K253463 was decided on July 2, 2026 for the ILR ECG Analyzer (IM007).

The vendor lists the ILR ECG Analyzer and AF Alert Management as CE-marked Class I under the MDD. SignalHF has no CE mark and, per the homepage, is "not available for sale in Europe."

What do the two papers and the vendor figures show?

Crespin and colleagues in Europace, 2023 (PMID 38170474), tested the insertable-monitor algorithm on 546 patients and 879 abnormal episodes and reported specificity of 76.0% and sensitivity of 98.6% against an adjudication committee. Lazarus and colleagues in Cardiovascular Digital Health Journal, 2023 (PMID 37850045), studied alert filtering and atrial fibrillation reclassification. Both have Implicity authors.

For SignalHF, PubMed holds no validation paper. The vendor cites Health Data Hub data and says 75% of alerts before a hospitalization came at least 14 days ahead. For the ILR ECG Analyzer, the homepage claims 79% fewer false positives on Medtronic loop recorder recordings at 99% sensitivity. For the platform as a whole, a funding-news page reports the vendor's claim of 26% lower mortality and 4% fewer hospitalizations than conventional remote monitoring, plus more than 250 medical centers and over 120,000 patients monitored daily across the US, France and Germany.

Where does the company stand?

Dr Arnaud Rosier, an electrophysiologist, founded Implicity in 2016, and US operations in Cambridge began in 2022. Funding coverage lists a $23 million Series A in 2022 led by Credit Mutuel Innovation and Bpifrance, then a EUR 35 million growth round (USD 40 million in US coverage) on September 9, 2026 led by IRIS with Five Arrows. Tech Funding News puts the total at about $69 million.

The homepage shows ISO 13485, ISO 27001 and the French HDS hosting logos and does not state HIPAA, SOC 2 or GDPR compliance. A funding-news profile says the platform "can integrate with electronic health records" and names none. Implicity sells by quote.

The verdict

A device clinic with mixed-manufacturer implants is the buyer Implicity describes. For the ILR ECG Analyzer it offers a 2026 clearance and a 546-patient paper by its own authors, and for SignalHF a 2023 clearance and vendor figures. A clinic whose patients all use one manufacturer's devices is outside the multi-manufacturer case the platform is built around.